| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tomography, X-Ray Computed | 89 | 2021 | 2441 | 12.780 |
Why?
|
| Lung Diseases, Interstitial | 27 | 2020 | 187 | 9.340 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 17 | 2021 | 119 | 6.480 |
Why?
|
| Lung | 29 | 2020 | 1002 | 4.880 |
Why?
|
| Radiography, Thoracic | 21 | 2020 | 401 | 4.290 |
Why?
|
| Lung Neoplasms | 20 | 2019 | 1993 | 3.090 |
Why?
|
| Alveolitis, Extrinsic Allergic | 5 | 2020 | 26 | 2.560 |
Why?
|
| Lymph Nodes | 7 | 2019 | 507 | 2.400 |
Why?
|
| Diagnosis, Differential | 32 | 2019 | 1560 | 2.320 |
Why?
|
| Diagnostic Imaging | 11 | 2019 | 424 | 2.240 |
Why?
|
| Humans | 156 | 2021 | 75301 | 2.010 |
Why?
|
| Idiopathic Interstitial Pneumonias | 9 | 2019 | 30 | 1.800 |
Why?
|
| Solitary Pulmonary Nodule | 5 | 2018 | 170 | 1.740 |
Why?
|
| Dyspnea | 5 | 2020 | 77 | 1.730 |
Why?
|
| Incidental Findings | 5 | 2018 | 96 | 1.690 |
Why?
|
| Lung Diseases | 8 | 2019 | 275 | 1.680 |
Why?
|
| Utilization Review | 2 | 2019 | 23 | 1.630 |
Why?
|
| Radiology | 11 | 2019 | 180 | 1.550 |
Why?
|
| Multiple Pulmonary Nodules | 3 | 2018 | 13 | 1.490 |
Why?
|
| Radiology Department, Hospital | 2 | 2018 | 26 | 1.450 |
Why?
|
| Middle Aged | 64 | 2021 | 23980 | 1.440 |
Why?
|
| Cough | 3 | 2020 | 45 | 1.430 |
Why?
|
| Aortic Diseases | 3 | 2019 | 103 | 1.360 |
Why?
|
| Pulmonary Fibrosis | 6 | 2020 | 115 | 1.350 |
Why?
|
| Interdisciplinary Communication | 2 | 2018 | 130 | 1.340 |
Why?
|
| Aorta, Thoracic | 3 | 2019 | 150 | 1.320 |
Why?
|
| Diagnostic Errors | 2 | 2018 | 173 | 1.310 |
Why?
|
| Aged | 48 | 2021 | 17101 | 1.300 |
Why?
|
| Practice Guidelines as Topic | 10 | 2019 | 1028 | 1.270 |
Why?
|
| Thoracic Injuries | 5 | 2014 | 25 | 1.260 |
Why?
|
| Female | 72 | 2021 | 41483 | 1.250 |
Why?
|
| Wounds, Nonpenetrating | 3 | 2014 | 58 | 1.250 |
Why?
|
| Male | 70 | 2021 | 39121 | 1.240 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2019 | 2961 | 1.170 |
Why?
|
| Scleroderma, Systemic | 3 | 2020 | 40 | 1.160 |
Why?
|
| Mediastinum | 3 | 2019 | 46 | 1.080 |
Why?
|
| Biopsy | 7 | 2020 | 1108 | 1.080 |
Why?
|
| Mucin-5B | 3 | 2019 | 12 | 1.060 |
Why?
|
| Contrast Media | 14 | 2019 | 994 | 1.060 |
Why?
|
| Connective Tissue Diseases | 4 | 2018 | 63 | 0.990 |
Why?
|
| Pulmonary Embolism | 3 | 2020 | 178 | 0.980 |
Why?
|
| Phthalazines | 2 | 2018 | 24 | 0.980 |
Why?
|
| Radiology Information Systems | 3 | 2018 | 85 | 0.970 |
Why?
|
| Pleura | 3 | 2020 | 30 | 0.950 |
Why?
|
| Sarcoidosis, Pulmonary | 3 | 2019 | 16 | 0.950 |
Why?
|
| Coronary Artery Disease | 4 | 2019 | 314 | 0.930 |
Why?
|
| Early Detection of Cancer | 3 | 2018 | 262 | 0.930 |
Why?
|
| Pulmonary Artery | 4 | 2019 | 273 | 0.920 |
Why?
|
| BRCA2 Protein | 2 | 2018 | 120 | 0.910 |
Why?
|
| Sensitivity and Specificity | 13 | 2021 | 2046 | 0.910 |
Why?
|
| Lymphatic Metastasis | 5 | 2019 | 491 | 0.890 |
Why?
|
| Fluorodeoxyglucose F18 | 8 | 2018 | 114 | 0.890 |
Why?
|
| Survival Analysis | 5 | 2018 | 1550 | 0.880 |
Why?
|
| Radiopharmaceuticals | 8 | 2018 | 155 | 0.880 |
Why?
|
| Reproducibility of Results | 11 | 2021 | 2605 | 0.870 |
Why?
|
| Piperazines | 2 | 2018 | 257 | 0.860 |
Why?
|
| Quality Assurance, Health Care | 2 | 2018 | 222 | 0.850 |
Why?
|
| Pleural Diseases | 2 | 2016 | 12 | 0.850 |
Why?
|
| Coronary Angiography | 6 | 2019 | 213 | 0.840 |
Why?
|
| Granuloma | 3 | 2016 | 53 | 0.840 |
Why?
|
| Positron-Emission Tomography | 6 | 2016 | 250 | 0.830 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2018 | 275 | 0.810 |
Why?
|
| Pneumonia, Bacterial | 2 | 2016 | 22 | 0.800 |
Why?
|
| Pulmonary Alveoli | 2 | 2016 | 85 | 0.800 |
Why?
|
| Predictive Value of Tests | 5 | 2019 | 1582 | 0.800 |
Why?
|
| Allied Health Personnel | 1 | 2018 | 12 | 0.790 |
Why?
|
| Autoimmune Diseases | 2 | 2017 | 223 | 0.790 |
Why?
|
| Retrospective Studies | 21 | 2019 | 6435 | 0.780 |
Why?
|
| Urothelium | 1 | 2018 | 60 | 0.770 |
Why?
|
| Feedback | 1 | 2018 | 104 | 0.760 |
Why?
|
| Technology, Radiologic | 1 | 2018 | 103 | 0.760 |
Why?
|
| Gadolinium | 3 | 2014 | 90 | 0.740 |
Why?
|
| Physician Incentive Plans | 1 | 2016 | 20 | 0.720 |
Why?
|
| Efficiency | 1 | 2016 | 34 | 0.710 |
Why?
|
| Speech Recognition Software | 1 | 2016 | 6 | 0.710 |
Why?
|
| Fibrosis | 6 | 2020 | 166 | 0.700 |
Why?
|
| Medical Audit | 1 | 2016 | 38 | 0.700 |
Why?
|
| Peer Review | 1 | 2016 | 18 | 0.700 |
Why?
|
| Tracheomalacia | 1 | 2016 | 2 | 0.690 |
Why?
|
| Adult | 38 | 2021 | 24240 | 0.690 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2016 | 5 | 0.680 |
Why?
|
| Medical Records | 1 | 2016 | 129 | 0.680 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2016 | 45 | 0.660 |
Why?
|
| Prevalence | 7 | 2019 | 1114 | 0.660 |
Why?
|
| Prognosis | 13 | 2020 | 3424 | 0.660 |
Why?
|
| Gases | 1 | 2015 | 27 | 0.650 |
Why?
|
| Magnetic Resonance Imaging, Cine | 3 | 2013 | 150 | 0.650 |
Why?
|
| Birt-Hogg-Dube Syndrome | 2 | 2014 | 2 | 0.650 |
Why?
|
| Breast Implants | 1 | 2015 | 31 | 0.650 |
Why?
|
| Cohort Studies | 12 | 2019 | 2426 | 0.640 |
Why?
|
| Cryptogenic Organizing Pneumonia | 2 | 2012 | 6 | 0.640 |
Why?
|
| Lymphangioleiomyomatosis | 2 | 2014 | 9 | 0.640 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 355 | 0.640 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2014 | 20 | 0.630 |
Why?
|
| Tracheal Diseases | 2 | 2013 | 11 | 0.630 |
Why?
|
| Calcinosis | 1 | 2016 | 240 | 0.630 |
Why?
|
| Psoriasis | 4 | 2018 | 203 | 0.620 |
Why?
|
| Academic Medical Centers | 2 | 2018 | 357 | 0.620 |
Why?
|
| Faculty, Medical | 1 | 2016 | 153 | 0.610 |
Why?
|
| Motivation | 1 | 2016 | 218 | 0.610 |
Why?
|
| Lung Transplantation | 2 | 2018 | 227 | 0.610 |
Why?
|
| Carcinoma | 1 | 2018 | 429 | 0.600 |
Why?
|
| Lymphatic Diseases | 1 | 2014 | 38 | 0.600 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2014 | 21 | 0.590 |
Why?
|
| Societies, Medical | 11 | 2020 | 477 | 0.590 |
Why?
|
| Cysts | 2 | 2014 | 99 | 0.590 |
Why?
|
| Pulmonary Valve | 2 | 2020 | 24 | 0.590 |
Why?
|
| Chronic Disease | 7 | 2020 | 898 | 0.580 |
Why?
|
| Testicular Neoplasms | 3 | 2019 | 103 | 0.570 |
Why?
|
| Sarcoidosis | 1 | 2014 | 85 | 0.560 |
Why?
|
| Pulmonary Circulation | 2 | 2012 | 82 | 0.550 |
Why?
|
| Ventricular Septum | 1 | 2012 | 13 | 0.550 |
Why?
|
| Mass Screening | 1 | 2017 | 574 | 0.550 |
Why?
|
| Pulmonary Subvalvular Stenosis | 1 | 2012 | 1 | 0.540 |
Why?
|
| United States | 17 | 2020 | 5574 | 0.540 |
Why?
|
| Echocardiography | 4 | 2020 | 766 | 0.520 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2012 | 69 | 0.520 |
Why?
|
| Systole | 1 | 2012 | 138 | 0.520 |
Why?
|
| Aneurysm | 1 | 2012 | 53 | 0.520 |
Why?
|
| Image Enhancement | 2 | 2013 | 663 | 0.520 |
Why?
|
| Evidence-Based Medicine | 9 | 2019 | 413 | 0.510 |
Why?
|
| Lymphomatoid Granulomatosis | 1 | 2011 | 6 | 0.510 |
Why?
|
| Myocardial Ischemia | 1 | 2013 | 161 | 0.510 |
Why?
|
| Smoking | 3 | 2017 | 542 | 0.500 |
Why?
|
| Pulmonary Infarction | 1 | 2010 | 1 | 0.480 |
Why?
|
| Disease Progression | 5 | 2019 | 1354 | 0.480 |
Why?
|
| Immunocompromised Host | 3 | 2019 | 128 | 0.480 |
Why?
|
| Hematoma | 1 | 2011 | 77 | 0.480 |
Why?
|
| Respiratory Distress Syndrome, Adult | 2 | 2015 | 94 | 0.470 |
Why?
|
| Lung Diseases, Fungal | 1 | 2010 | 25 | 0.470 |
Why?
|
| Mucormycosis | 1 | 2010 | 15 | 0.460 |
Why?
|
| Mitral Valve | 1 | 2012 | 205 | 0.460 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 284 | 0.450 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 307 | 0.450 |
Why?
|
| Genomics | 6 | 2021 | 536 | 0.450 |
Why?
|
| Amyloidosis | 1 | 2010 | 75 | 0.450 |
Why?
|
| Pulmonary Alveolar Proteinosis | 1 | 2009 | 4 | 0.430 |
Why?
|
| Antineoplastic Agents | 6 | 2019 | 2280 | 0.430 |
Why?
|
| Graft Rejection | 1 | 2016 | 1088 | 0.420 |
Why?
|
| Heart Diseases | 1 | 2012 | 297 | 0.420 |
Why?
|
| Colorado | 3 | 2019 | 34 | 0.410 |
Why?
|
| Asthma | 1 | 2016 | 773 | 0.410 |
Why?
|
| Receptor, erbB-2 | 3 | 2020 | 184 | 0.410 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 2133 | 0.400 |
Why?
|
| DNA, Neoplasm | 2 | 2020 | 271 | 0.400 |
Why?
|
| Radiographic Image Enhancement | 4 | 2016 | 530 | 0.390 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2020 | 127 | 0.390 |
Why?
|
| Phenotype | 5 | 2019 | 2098 | 0.390 |
Why?
|
| Cystectomy | 2 | 2018 | 57 | 0.390 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2018 | 113 | 0.380 |
Why?
|
| Aorta | 2 | 2020 | 270 | 0.380 |
Why?
|
| Heart Defects, Congenital | 2 | 2018 | 323 | 0.370 |
Why?
|
| Observer Variation | 3 | 2017 | 746 | 0.370 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2018 | 873 | 0.370 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2019 | 92 | 0.370 |
Why?
|
| Respiratory Tract Infections | 3 | 2019 | 92 | 0.360 |
Why?
|
| Respiratory Tract Diseases | 2 | 2018 | 44 | 0.360 |
Why?
|
| Mutation | 4 | 2020 | 3570 | 0.360 |
Why?
|
| Abnormalities, Multiple | 1 | 2008 | 237 | 0.360 |
Why?
|
| Respiratory-Gated Imaging Techniques | 2 | 2016 | 4 | 0.350 |
Why?
|
| Hematologic Neoplasms | 1 | 2009 | 266 | 0.340 |
Why?
|
| Multivariate Analysis | 6 | 2018 | 992 | 0.340 |
Why?
|
| Liver Neoplasms | 3 | 2017 | 589 | 0.330 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2017 | 140 | 0.320 |
Why?
|
| Aged, 80 and over | 10 | 2021 | 6136 | 0.320 |
Why?
|
| Feasibility Studies | 3 | 2020 | 682 | 0.310 |
Why?
|
| Genotype | 3 | 2016 | 1783 | 0.310 |
Why?
|
| Algorithms | 7 | 2019 | 1878 | 0.310 |
Why?
|
| Stroke | 1 | 2012 | 694 | 0.310 |
Why?
|
| Angiography | 3 | 2014 | 195 | 0.290 |
Why?
|
| Hypertension, Pulmonary | 3 | 2018 | 311 | 0.290 |
Why?
|
| Biological Specimen Banks | 2 | 2020 | 36 | 0.280 |
Why?
|
| Carcinoma, Bronchogenic | 2 | 2013 | 31 | 0.280 |
Why?
|
| Hemoptysis | 2 | 2014 | 23 | 0.270 |
Why?
|
| Serologic Tests | 2 | 2020 | 45 | 0.260 |
Why?
|
| Software | 3 | 2018 | 625 | 0.260 |
Why?
|
| Pandemics | 3 | 2020 | 335 | 0.260 |
Why?
|
| Medical History Taking | 2 | 2020 | 78 | 0.250 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2019 | 36 | 0.250 |
Why?
|
| Pancreatic Neoplasms | 2 | 2019 | 681 | 0.250 |
Why?
|
| Neoplasm Staging | 6 | 2019 | 1867 | 0.250 |
Why?
|
| Molecular Targeted Therapy | 3 | 2019 | 248 | 0.250 |
Why?
|
| Genetic Variation | 2 | 2019 | 1313 | 0.250 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2019 | 1147 | 0.240 |
Why?
|
| Atrial Septum | 2 | 2010 | 7 | 0.240 |
Why?
|
| Internship and Residency | 1 | 2009 | 809 | 0.240 |
Why?
|
| Inhalation Exposure | 1 | 2020 | 21 | 0.230 |
Why?
|
| Gastropexy | 1 | 2020 | 1 | 0.230 |
Why?
|
| Heart Septal Defects, Atrial | 2 | 2010 | 59 | 0.230 |
Why?
|
| Ossification, Heterotopic | 1 | 2020 | 30 | 0.230 |
Why?
|
| Bronchiolitis | 3 | 2015 | 4 | 0.230 |
Why?
|
| Treatment Outcome | 7 | 2020 | 7300 | 0.230 |
Why?
|
| Piperidines | 2 | 2018 | 151 | 0.230 |
Why?
|
| Radiation Dosage | 2 | 2019 | 224 | 0.230 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2020 | 124 | 0.230 |
Why?
|
| Coronavirus | 1 | 2020 | 16 | 0.220 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2016 | 650 | 0.220 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 20 | 0.220 |
Why?
|
| Gastrostomy | 1 | 2020 | 75 | 0.220 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 1 | 2019 | 10 | 0.220 |
Why?
|
| Survival Rate | 3 | 2019 | 1852 | 0.220 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2019 | 46 | 0.220 |
Why?
|
| Ultrasonography, Interventional | 1 | 2020 | 105 | 0.220 |
Why?
|
| Urologic Neoplasms | 1 | 2020 | 62 | 0.210 |
Why?
|
| Autoimmunity | 2 | 2018 | 159 | 0.210 |
Why?
|
| Medicare Part B | 1 | 2019 | 3 | 0.210 |
Why?
|
| Cardiovascular Diseases | 2 | 2018 | 723 | 0.210 |
Why?
|
| Artifacts | 3 | 2019 | 224 | 0.210 |
Why?
|
| Hematopoietic System | 1 | 2018 | 14 | 0.210 |
Why?
|
| Referral and Consultation | 2 | 2019 | 290 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2018 | 17 | 0.210 |
Why?
|
| Multidetector Computed Tomography | 2 | 2018 | 54 | 0.210 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2019 | 46 | 0.210 |
Why?
|
| Seminoma | 1 | 2018 | 13 | 0.210 |
Why?
|
| Mediastinal Neoplasms | 1 | 2019 | 51 | 0.200 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2020 | 106 | 0.200 |
Why?
|
| Carcinoma, Large Cell | 1 | 2018 | 40 | 0.200 |
Why?
|
| Quinazolines | 2 | 2018 | 219 | 0.200 |
Why?
|
| Parathyroid Neoplasms | 1 | 2018 | 62 | 0.200 |
Why?
|
| Comparative Effectiveness Research | 2 | 2016 | 44 | 0.200 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 524 | 0.200 |
Why?
|
| Carbazoles | 1 | 2018 | 49 | 0.200 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2019 | 62 | 0.200 |
Why?
|
| Amygdala | 1 | 2018 | 70 | 0.200 |
Why?
|
| Drug Substitution | 1 | 2018 | 24 | 0.200 |
Why?
|
| Gene Expression Profiling | 3 | 2019 | 1381 | 0.200 |
Why?
|
| Statistics as Topic | 2 | 2017 | 324 | 0.200 |
Why?
|
| Lymphocytes | 1 | 2020 | 460 | 0.190 |
Why?
|
| Pulmonary Emphysema | 1 | 2017 | 20 | 0.190 |
Why?
|
| Occupational Diseases | 2 | 2016 | 53 | 0.190 |
Why?
|
| Risk Factors | 6 | 2019 | 4896 | 0.190 |
Why?
|
| Vasculitis | 1 | 2017 | 41 | 0.190 |
Why?
|
| Free Radical Scavengers | 1 | 2018 | 62 | 0.190 |
Why?
|
| Intra-Abdominal Fat | 1 | 2017 | 26 | 0.190 |
Why?
|
| Subcutaneous Fat | 1 | 2017 | 23 | 0.190 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2016 | 2200 | 0.190 |
Why?
|
| Acetylcysteine | 1 | 2018 | 74 | 0.190 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2018 | 74 | 0.190 |
Why?
|
| Risk Assessment | 4 | 2020 | 2074 | 0.190 |
Why?
|
| Antirheumatic Agents | 1 | 2017 | 48 | 0.190 |
Why?
|
| Adiposity | 1 | 2017 | 75 | 0.190 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2017 | 29 | 0.180 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2017 | 35 | 0.180 |
Why?
|
| Registries | 2 | 2017 | 553 | 0.180 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2016 | 18 | 0.180 |
Why?
|
| Case-Control Studies | 3 | 2018 | 1719 | 0.180 |
Why?
|
| Radionuclide Imaging | 1 | 2017 | 236 | 0.180 |
Why?
|
| Pathology, Clinical | 1 | 2017 | 35 | 0.180 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2016 | 22 | 0.180 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2016 | 4 | 0.180 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 3 | 2019 | 488 | 0.180 |
Why?
|
| Software Validation | 1 | 2016 | 4 | 0.180 |
Why?
|
| Prospective Studies | 6 | 2021 | 3554 | 0.170 |
Why?
|
| Myositis | 1 | 2016 | 12 | 0.170 |
Why?
|
| Mycobacterium avium Complex | 1 | 2016 | 8 | 0.170 |
Why?
|
| Hyperlipidemias | 1 | 2017 | 131 | 0.170 |
Why?
|
| Azathioprine | 1 | 2016 | 119 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2018 | 817 | 0.170 |
Why?
|
| Promoter Regions, Genetic | 2 | 2019 | 907 | 0.170 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2017 | 348 | 0.170 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2018 | 398 | 0.170 |
Why?
|
| Atmospheric Pressure | 1 | 2015 | 4 | 0.170 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2017 | 159 | 0.170 |
Why?
|
| Hospitalization | 2 | 2018 | 652 | 0.160 |
Why?
|
| Atrial Fibrillation | 1 | 2018 | 216 | 0.160 |
Why?
|
| Altitude | 1 | 2015 | 36 | 0.160 |
Why?
|
| Neuroendocrine Cells | 1 | 2015 | 2 | 0.160 |
Why?
|
| Stress, Psychological | 1 | 2018 | 281 | 0.160 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2017 | 186 | 0.160 |
Why?
|
| Rib Fractures | 1 | 2014 | 4 | 0.160 |
Why?
|
| Cystic Fibrosis | 1 | 2016 | 123 | 0.150 |
Why?
|
| Pneumonia, Aspiration | 1 | 2014 | 17 | 0.150 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2018 | 344 | 0.150 |
Why?
|
| Guideline Adherence | 1 | 2016 | 214 | 0.150 |
Why?
|
| Breast Neoplasms | 2 | 2018 | 2567 | 0.150 |
Why?
|
| Heterozygote | 1 | 2016 | 360 | 0.150 |
Why?
|
| Acute Disease | 4 | 2019 | 822 | 0.150 |
Why?
|
| Carrier Proteins | 1 | 2018 | 674 | 0.150 |
Why?
|
| Prosthesis Failure | 1 | 2015 | 141 | 0.150 |
Why?
|
| Heart Ventricles | 1 | 2020 | 684 | 0.150 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2014 | 20 | 0.150 |
Why?
|
| Emphysema | 1 | 2014 | 14 | 0.150 |
Why?
|
| Pneumonia, Mycoplasma | 1 | 2014 | 6 | 0.150 |
Why?
|
| Glass | 1 | 2014 | 15 | 0.150 |
Why?
|
| Biopsy, Needle | 2 | 2012 | 266 | 0.150 |
Why?
|
| Bronchoscopy | 4 | 2020 | 127 | 0.150 |
Why?
|
| Bronchial Diseases | 1 | 2013 | 12 | 0.140 |
Why?
|
| Immunosuppressive Agents | 2 | 2016 | 1004 | 0.140 |
Why?
|
| User-Computer Interface | 2 | 2012 | 178 | 0.140 |
Why?
|
| Patient Care Team | 1 | 2016 | 245 | 0.140 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 611 | 0.140 |
Why?
|
| Thorax | 1 | 2013 | 52 | 0.140 |
Why?
|
| Protons | 1 | 2013 | 90 | 0.140 |
Why?
|
| Comorbidity | 1 | 2017 | 844 | 0.140 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2014 | 95 | 0.140 |
Why?
|
| Antibodies, Antinuclear | 3 | 2018 | 87 | 0.140 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 529 | 0.140 |
Why?
|
| Phantoms, Imaging | 2 | 2014 | 358 | 0.140 |
Why?
|
| DiGeorge Syndrome | 1 | 2012 | 11 | 0.140 |
Why?
|
| Cleft Palate | 1 | 2012 | 23 | 0.140 |
Why?
|
| Mediastinitis | 1 | 2012 | 14 | 0.140 |
Why?
|
| Histoplasmosis | 1 | 2012 | 22 | 0.130 |
Why?
|
| Pulmonary Diffusing Capacity | 3 | 2017 | 24 | 0.130 |
Why?
|
| Dilatation, Pathologic | 1 | 2012 | 56 | 0.130 |
Why?
|
| Vital Capacity | 3 | 2017 | 53 | 0.130 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2012 | 38 | 0.130 |
Why?
|
| Cardiac-Gated Imaging Techniques | 1 | 2012 | 21 | 0.130 |
Why?
|
| Pericarditis, Constrictive | 1 | 2012 | 5 | 0.130 |
Why?
|
| Chicago | 1 | 2017 | 1292 | 0.130 |
Why?
|
| Critical Care | 1 | 2015 | 323 | 0.130 |
Why?
|
| Cardiac Tamponade | 1 | 2012 | 18 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2011 | 23 | 0.130 |
Why?
|
| Atlases as Topic | 1 | 2011 | 7 | 0.130 |
Why?
|
| Alleles | 1 | 2016 | 1083 | 0.130 |
Why?
|
| Heart Septum | 1 | 2012 | 45 | 0.130 |
Why?
|
| Thoracic Diseases | 1 | 2012 | 29 | 0.130 |
Why?
|
| T-Box Domain Proteins | 1 | 2012 | 84 | 0.120 |
Why?
|
| Inflammation | 1 | 2017 | 844 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 1002 | 0.120 |
Why?
|
| Polymorphism, Genetic | 1 | 2016 | 819 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 1446 | 0.120 |
Why?
|
| Tomography, Spiral Computed | 1 | 2011 | 80 | 0.120 |
Why?
|
| Bronchiectasis | 1 | 2010 | 12 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 3 | 2019 | 511 | 0.120 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2012 | 154 | 0.120 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 269 | 0.120 |
Why?
|
| Cardiomyopathies | 1 | 2013 | 216 | 0.120 |
Why?
|
| Hypotension | 1 | 2010 | 67 | 0.110 |
Why?
|
| Protein Kinases | 1 | 2011 | 211 | 0.110 |
Why?
|
| African Americans | 1 | 2018 | 1018 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2018 | 1196 | 0.110 |
Why?
|
| Adipose Tissue | 1 | 2012 | 231 | 0.110 |
Why?
|
| Longitudinal Studies | 3 | 2017 | 865 | 0.110 |
Why?
|
| Fever | 1 | 2010 | 113 | 0.110 |
Why?
|
| Delphi Technique | 3 | 2014 | 54 | 0.110 |
Why?
|
| Bacteremia | 1 | 2010 | 105 | 0.110 |
Why?
|
| Logistic Models | 3 | 2018 | 1091 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2018 | 865 | 0.110 |
Why?
|
| Trachea | 1 | 2011 | 304 | 0.110 |
Why?
|
| Washington | 1 | 2009 | 39 | 0.110 |
Why?
|
| Respiratory Function Tests | 2 | 2019 | 133 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 3613 | 0.100 |
Why?
|
| HIV Infections | 1 | 2016 | 599 | 0.100 |
Why?
|
| Professional Competence | 1 | 2009 | 72 | 0.100 |
Why?
|
| Cell Cycle Proteins | 1 | 2011 | 342 | 0.100 |
Why?
|
| Palliative Care | 1 | 2010 | 236 | 0.100 |
Why?
|
| Smoking Cessation | 1 | 2010 | 160 | 0.100 |
Why?
|
| Protein-Serine-Threonine Kinases | 1 | 2011 | 531 | 0.090 |
Why?
|
| Young Adult | 4 | 2020 | 5341 | 0.090 |
Why?
|
| Gene Rearrangement | 2 | 2018 | 157 | 0.090 |
Why?
|
| Colonic Neoplasms | 1 | 2011 | 532 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2012 | 719 | 0.090 |
Why?
|
| DNA Mutational Analysis | 2 | 2018 | 518 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 371 | 0.080 |
Why?
|
| Neoplasms | 1 | 2019 | 2362 | 0.080 |
Why?
|
| Forced Expiratory Volume | 2 | 2015 | 104 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 721 | 0.080 |
Why?
|
| Patient Selection | 2 | 2020 | 654 | 0.080 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 815 | 0.080 |
Why?
|
| Time Factors | 3 | 2020 | 5245 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2010 | 1150 | 0.070 |
Why?
|
| Iopamidol | 2 | 2013 | 8 | 0.070 |
Why?
|
| Radiography | 2 | 2016 | 847 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 1647 | 0.070 |
Why?
|
| ROC Curve | 2 | 2019 | 855 | 0.070 |
Why?
|
| Adolescent | 3 | 2020 | 8442 | 0.070 |
Why?
|
| Signal Transduction | 3 | 2019 | 3174 | 0.060 |
Why?
|
| New York | 1 | 2020 | 58 | 0.060 |
Why?
|
| Cryosurgery | 1 | 2020 | 38 | 0.060 |
Why?
|
| Ontario | 1 | 2020 | 51 | 0.060 |
Why?
|
| Cardiac Output | 1 | 2020 | 147 | 0.060 |
Why?
|
| North America | 1 | 2020 | 170 | 0.060 |
Why?
|
| Telomerase | 1 | 2019 | 43 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 2064 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2021 | 492 | 0.050 |
Why?
|
| Genomic Structural Variation | 1 | 2019 | 3 | 0.050 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 57 | 0.050 |
Why?
|
| Organ Size | 1 | 2020 | 372 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2018 | 2306 | 0.050 |
Why?
|
| ras Guanine Nucleotide Exchange Factors | 1 | 2018 | 9 | 0.050 |
Why?
|
| Nuclear Receptor Coactivators | 1 | 2018 | 4 | 0.050 |
Why?
|
| Neurofibromin 1 | 1 | 2018 | 7 | 0.050 |
Why?
|
| INDEL Mutation | 1 | 2018 | 22 | 0.050 |
Why?
|
| Motion | 1 | 2019 | 70 | 0.050 |
Why?
|
| Consensus | 1 | 2020 | 235 | 0.050 |
Why?
|
| Equipment Design | 1 | 2020 | 405 | 0.050 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 42 | 0.050 |
Why?
|
| Italy | 1 | 2018 | 92 | 0.050 |
Why?
|
| NIH 3T3 Cells | 1 | 2018 | 103 | 0.050 |
Why?
|
| Asymptomatic Diseases | 1 | 2018 | 36 | 0.050 |
Why?
|
| Anilides | 1 | 2018 | 44 | 0.050 |
Why?
|
| Mutation Rate | 1 | 2018 | 42 | 0.050 |
Why?
|
| Child | 2 | 2019 | 6125 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 454 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2020 | 676 | 0.050 |
Why?
|
| Propensity Score | 1 | 2018 | 113 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 132 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2018 | 292 | 0.050 |
Why?
|
| Loss of Heterozygosity | 1 | 2017 | 87 | 0.050 |
Why?
|
| Phototherapy | 1 | 2017 | 31 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2019 | 269 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2019 | 169 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2018 | 232 | 0.050 |
Why?
|
| Rheumatoid Factor | 1 | 2017 | 17 | 0.050 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 165 | 0.050 |
Why?
|
| Whole Body Imaging | 1 | 2017 | 36 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2018 | 231 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2017 | 143 | 0.050 |
Why?
|
| Cause of Death | 1 | 2018 | 261 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2017 | 297 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 421 | 0.050 |
Why?
|
| Pneumocystis carinii | 1 | 2016 | 2 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2015 | 1517 | 0.040 |
Why?
|
| Hypersplenism | 1 | 2016 | 2 | 0.040 |
Why?
|
| Cholesterol, HDL | 1 | 2017 | 201 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2017 | 171 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2018 | 762 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 1 | 2018 | 244 | 0.040 |
Why?
|
| Heart Rate | 1 | 2019 | 481 | 0.040 |
Why?
|
| Mycophenolic Acid | 1 | 2016 | 86 | 0.040 |
Why?
|
| Risk | 1 | 2018 | 675 | 0.040 |
Why?
|
| Leukopenia | 1 | 2016 | 64 | 0.040 |
Why?
|
| Pyridines | 1 | 2018 | 287 | 0.040 |
Why?
|
| Arthritis | 1 | 2016 | 42 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2017 | 359 | 0.040 |
Why?
|
| Anthracosis | 1 | 2016 | 1 | 0.040 |
Why?
|
| Silicosis | 1 | 2016 | 2 | 0.040 |
Why?
|
| Asbestosis | 1 | 2016 | 5 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 951 | 0.040 |
Why?
|
| Creatine Kinase | 1 | 2016 | 52 | 0.040 |
Why?
|
| Genome | 1 | 2019 | 326 | 0.040 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2016 | 106 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 347 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 327 | 0.040 |
Why?
|
| Sequence Alignment | 1 | 2016 | 354 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2017 | 374 | 0.040 |
Why?
|
| Neuroblastoma | 1 | 2020 | 441 | 0.040 |
Why?
|
| Animals | 2 | 2018 | 25499 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 430 | 0.040 |
Why?
|
| Protein Multimerization | 1 | 2016 | 169 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 1190 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 254 | 0.040 |
Why?
|
| Chromosome Mapping | 1 | 2019 | 1088 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2017 | 320 | 0.040 |
Why?
|
| Physical Examination | 1 | 2016 | 143 | 0.040 |
Why?
|
| Lung Abscess | 1 | 2014 | 7 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2015 | 153 | 0.040 |
Why?
|
| Multiple Trauma | 1 | 2014 | 30 | 0.040 |
Why?
|
| Thoracic Wall | 1 | 2014 | 20 | 0.040 |
Why?
|
| Diaphragm | 1 | 2014 | 51 | 0.040 |
Why?
|
| Pleural Effusion | 1 | 2014 | 46 | 0.040 |
Why?
|
| Aortography | 1 | 2014 | 60 | 0.040 |
Why?
|
| Lung Injury | 1 | 2014 | 44 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 1192 | 0.040 |
Why?
|
| Chest Pain | 1 | 2014 | 40 | 0.040 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2014 | 92 | 0.040 |
Why?
|
| Foreign Bodies | 1 | 2014 | 55 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2014 | 97 | 0.040 |
Why?
|
| Tracheal Neoplasms | 1 | 2013 | 7 | 0.040 |
Why?
|
| Ventilation-Perfusion Ratio | 1 | 2013 | 14 | 0.040 |
Why?
|
| Evidence-Based Dentistry | 1 | 2013 | 9 | 0.040 |
Why?
|
| Bronchial Neoplasms | 1 | 2013 | 10 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 2056 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 522 | 0.040 |
Why?
|
| Protein Conformation | 1 | 2016 | 856 | 0.040 |
Why?
|
| Airway Obstruction | 1 | 2014 | 111 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 663 | 0.030 |
Why?
|
| Gene Order | 1 | 2012 | 25 | 0.030 |
Why?
|
| Inpatients | 1 | 2015 | 209 | 0.030 |
Why?
|
| Health Policy | 1 | 2014 | 153 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 430 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 369 | 0.030 |
Why?
|
| Collagen Diseases | 1 | 2012 | 3 | 0.030 |
Why?
|
| Mixed Connective Tissue Disease | 1 | 2012 | 2 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2020 | 3571 | 0.030 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2012 | 22 | 0.030 |
Why?
|
| Embolization, Therapeutic | 1 | 2014 | 179 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 752 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2015 | 322 | 0.030 |
Why?
|
| Liver | 1 | 2017 | 1185 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 1773 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2016 | 2138 | 0.030 |
Why?
|
| Echocardiography, Doppler | 1 | 2013 | 184 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2012 | 53 | 0.030 |
Why?
|
| Diastole | 1 | 2012 | 141 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 1380 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2011 | 336 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2012 | 201 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2016 | 766 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2012 | 656 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2014 | 1087 | 0.030 |
Why?
|
| Cell Survival | 1 | 2011 | 993 | 0.030 |
Why?
|
| Base Sequence | 1 | 2012 | 2390 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2010 | 510 | 0.020 |
Why?
|
| Mice | 1 | 2018 | 10400 | 0.020 |
Why?
|